Skip to content
Unknown statusPhase 4

Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy

NCT02267980 · Inonu University

Closed to entry
Status
Not accepting participants
Phase 4
Phase
60
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

The investigators evaluate the effects of a subanesthetic dose of ketamine, administered as an adjunct to sevoflurane, on duration of seizure activity, hemodynamic profile and recovery times during electroconvulsive therapy (ECT) in patients with major depression.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • seizure duration

    Measured over During electroconvulsive therapy (30 minutes)

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 70 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Major depressive patients Exclusion Criteria: * Pregnancy * Have a history of myocardial infarction in the previous six months * Atrial fibrillation or flutter * Heart block * Unregulated hypertension * Cerebrovascular diseases * A known drug allergy

Where

1 study site

FacilityCityRegionCountry
Turgut Ozal Medical CenterMalatyaTurkey (Türkiye)

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT02267980 on ClinicalTrials.gov →

Last updated in the registry 2014-10-20. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits